AGLE Share Price | Spyre Therapeutics, Inc. Stock Analysis & Recommendation

Q: How big is Spyre Therapeutics, Inc.?

Market Cap: As of Jun 18, Spyre Therapeutics, Inc. has a market capitalization of 916.17 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Spyre Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -160.22 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 517.80 million and total assets of 608.48 million.

Q: What does Spyre Therapeutics, Inc. do?

Overview:Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing human enzyme therapeutics for rare and high-burden diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot:Most recent Net Profit: -36 Million (Quarterly Results - Mar 2025) Market cap: USD 916.17 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.17 Return on Equity: -33.70% Price to Book: 1.90Contact Details:Address: 805 Las Cimas Parkway, Suite 100, AUSTIN TX: 78746 Tel: ['1 512 9422935', '1 512 9003661'] Fax: 1 512 8725121 Website: http://aegleabio.com

Q: Is Spyre Therapeutics, Inc. overvalued or undervalued?

As of 29 February 2024, the valuation grade for Spyre Therapeutics, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently deemed overvalued given its negative financial metrics, including a Price to Book Value of 2.12 and an EV to EBIT of -2.14. Additionally, the Return on Equity (ROE) stands at a concerning -33.70%, reflecting ongoing losses and a lack of profitability.In comparison to its peers, Spyre Therapeutics shows a stark contrast with companies like BioCryst Pharmaceuticals, which has a P/E ratio of -39.02, and AbCellera Biologics, with an EV to EBITDA of -1.35. These peers also reflect a risky valuation, but Spyre's metrics suggest it is not positioned favorably within this group. The recent stock performance has been poor, with a year-to-date return of -36.94%, significantly underperforming the S&P 500, which has returned 2.44% in the same period. Overall, Spyre Therapeutics is considered overvalued based on its current financial ratios and peer comparisons.

Q: Is Spyre Therapeutics, Inc. technically bullish or bearish?

As of 24 October 2025, the technical trend for Spyre Therapeutics, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and the daily moving averages also indicate a bullish stance. The weekly Bollinger Bands and KST are bullish, while the monthly Bollinger Bands and KST are mildly bearish. The Dow Theory shows a mildly bullish trend on both weekly and monthly time frames. In terms of performance, Spyre Therapeutics has outperformed the S&P 500 over the past week and month, returning 4.01% and 37.47% respectively, while the S&P 500 returned 1.92% and 2.32%. However, the year-to-date return is only 0.39%, significantly lagging behind the S&P 500's 15.47%. Overall, the current technical stance is bullish, driven by strong weekly indicators despite some mixed monthly signals.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

220.91 k

Shareholding (Dec 2025)

FII

9.02%

Held by 84 FIIs

DII

42.41%

Held by 46 DIIs

Promoter

11.35%

How big is Spyre Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Spyre Therapeutics, Inc. has a market capitalization of 916.17 million, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -160.22 million over the latest four quarters.

View full answer

What does Spyre Therapeutics, Inc. do?

22-Jun-2025

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing enzyme therapeutics for rare diseases, with a market cap of approximately $916.17 million and a recent net profit of -$36 million. The company is classified as a micro-cap and has no dividend yield.

View full answer

Who are in the management team of Spyre Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Spyre Therapeutics, Inc. includes Mr. Russell Cox (Independent Chairman), Dr. Anthony Quinn (President and CEO), and several independent directors: Ms. Alison Lawton, Dr. Suzanne Bruhn, Dr. V. Bryan Lawlis, Dr. Ivana Magovcevic-Liebisch, and Mr. Sandesh Mahatme. This team combines executive leadership with independent oversight.

View full answer

Is Spyre Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

As of February 29, 2024, Spyre Therapeutics, Inc. is considered overvalued and has deteriorated to a "does not qualify" valuation grade due to negative financial metrics, including a Price to Book Value of 2.12, an EV to EBIT of -2.14, and a Return on Equity of -33.70%, alongside poor stock performance and unfavorable comparisons to its peers.

View full answer

Is Spyre Therapeutics, Inc. technically bullish or bearish?

28-Oct-2025

As of October 24, 2025, Spyre Therapeutics, Inc. shows a bullish technical trend with strong weekly indicators, having outperformed the S&P 500 recently, although its year-to-date return lags behind the index.

View full answer

Compare Spyre Therapeutics, Inc. with Similar Stocks

Vir Biotechnology, Inc.Summit Therapeutics, Inc.Rhythm Pharmaceuticals, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 3,461 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.06

Return on Equity

-18.99%

Price to Book

4.84

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-52 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

38.21%

6 Months

168.71%

1 Year

140.17%

2 Years

10.87%

3 Years

13742.42%

4 Years

-27.2%

5 Years

-75.11%

Spyre Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-192.97%

EBIT to Interest (avg)

-109.06

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.17

Sales to Capital Employed (avg)

0.00

Tax Ratio

0.01%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

4.84

EV to EBIT

-12.32

EV to EBITDA

-12.32

EV to Capital Employed

-65.49

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-18.99%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Bullish

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Dow Theory

No Trend

OBV

No Trend

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 45 Schemes (37.23%)

Foreign Institutions

Held by 84 Foreign Institutions (9.02%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Sep 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -362.50% vs 69.48% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-57.20",
          "val2": "-56.90",
          "chgp": "-0.53%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-42.20",
          "val2": "40.40",
          "chgp": "-204.46%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-51.80",
          "val2": "-11.20",
          "chgp": "-362.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs -100.00% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 15.44% vs -57.64% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-219.60",
          "val2": "-208.60",
          "chgp": "-5.27%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-126.50",
          "val2": "-149.60",
          "chgp": "15.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-57.20

-56.90

-0.53%

Interest

0.00

Exceptional Items

-42.20

40.40

-204.46%

Consolidate Net Profit

-51.80

-11.20

-362.50%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is -362.50% vs 69.48% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-219.60

-208.60

-5.27%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-126.50

-149.60

15.44%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs -100.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 15.44% vs -57.64% in Dec 2024

All Annual Results

Company CV

About Spyre Therapeutics, Inc.

Spyre Therapeutics, Inc.

Pharmaceuticals & Biotechnology

Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a human enzyme therapeutics as advanced solutions for rare and other high-burden diseases. The Company’s product candidates are Pegzilarginase, ACN00177 and AEB5100. Its Pegzilarginase is a recombinant human Arginase one that enzymatically degrades the amino acid arginine to lower arginine levels in patients with Arginase One Deficiency. Its engineered pegzilarginase with modifications that enhance the stability and arginine-degrading activity of the enzyme in human plasma. The Company is evaluating Pegzilarginase in a global pivotal Phase III PEACE (Pegzilarginase Effect on Arginase one Deficiency Clinical Endpoints) trial and in a Phase II open-label extension study for patients with Arginase One Deficiency. Its ACN00177 is a PEGylated or polyethylene glycol modified, human enzyme engineered to degrade free homocysteine and homocystine in patients with Homocystinuria.

Company Coordinates

Company Details

805 Las Cimas Parkway, Suite 100 , AUSTIN TX : 78746

Tel: 1 512 94229351 512 9003661

http://aegleabio.com

Registrar Details